Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.

Adenocarcinoma / drug therapy Antineoplastic Combined Chemotherapy Protocols / therapeutic use Humans Neoadjuvant Therapy Pancreatic Neoplasms / drug therapy Retrospective Studies
Borderline pancreatic cancer R0 rate neoadjuvant treatment

Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 2 7 2021
medline: 25 8 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US). Between 2010 and 2017 patient records for all consecutive patients treated for BRPC according to NCCN 2017 were reviewed. The endpoints analysed were R0 rate, recurrence-free-survival (RFS) and overall survival (OS). Seventy-nine patients were included: 63 (79.7%) patients received NAT and 16 (20.3%) were upfront operated. NAT consisted in FOLFIRINOX (median cycles: 5, range 4-8) followed by chemoradiation ( NAT permitted a high R0 rate with a 0- or 1-mm clearance margin and was associated with better RFS and OS for patients with BRPC.

Sections du résumé

BACKGROUND BACKGROUND
Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US).
MATERIAL AND METHODS METHODS
Between 2010 and 2017 patient records for all consecutive patients treated for BRPC according to NCCN 2017 were reviewed. The endpoints analysed were R0 rate, recurrence-free-survival (RFS) and overall survival (OS).
RESULTS RESULTS
Seventy-nine patients were included: 63 (79.7%) patients received NAT and 16 (20.3%) were upfront operated. NAT consisted in FOLFIRINOX (median cycles: 5, range 4-8) followed by chemoradiation (
CONCLUSION CONCLUSIONS
NAT permitted a high R0 rate with a 0- or 1-mm clearance margin and was associated with better RFS and OS for patients with BRPC.

Identifiants

DOI: 10.1080/0284186X.2021.1944662 PMID: 34197269
pubmed: 34197269
doi: 10.1080/0284186X.2021.1944662
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1114-1121

Auteurs

Mario Terlizzi (M)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.
ORCID: 0000-0001-8496-6918

Etienne Buscail (E)

Département de Chirurgie, CHU Bordeaux, Bordeaux, France.

Olayidé Boussari (O)

Département de Biostatistiques, FFCD, Dijon, France.

Sarah Adgié (S)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.

Nicolas Leduc (N)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.

Eric Terrebonne (E)

Service d'Oncologie Médicale, CHU Bordeaux, Bordeaux, France.

Denis Smith (D)

Service d'Oncologie Médicale, CHU Bordeaux, Bordeaux, France.

Jean-Frédéric Blanc (JF)

Service d'Oncologie Médicale, CHU Bordeaux, Bordeaux, France.

Bruno Lapuyade (B)

Département d'Imagerie Médicale, CHU Bordeaux, Bordeaux, France.

Christophe Laurent (C)

Département de Chirurgie, CHU Bordeaux, Bordeaux, France.

Laurence Chiche (L)

Département de Chirurgie, CHU Bordeaux, Bordeaux, France.

Geneviève Belleannée (G)

Service d'Anatomopathologie, CHU Bordeaux, Bordeaux, France.

Karine Le Malicot (K)

Département de Biostatistiques, FFCD, Dijon, France.

Renaud Trouette (R)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.

Claudia Pouypoudat (C)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.

Véronique Vendrely (V)

Service de Radiothérapie, CHU Bordeaux, Bordeaux, France.
Département de Chirurgie, CHU Bordeaux, Bordeaux, France.
Département de Biostatistiques, FFCD, Dijon, France.
Service d'Oncologie Médicale, CHU Bordeaux, Bordeaux, France.
Département d'Imagerie Médicale, CHU Bordeaux, Bordeaux, France.
Service d'Anatomopathologie, CHU Bordeaux, Bordeaux, France.
INSERM U1035, BMGIC, University of Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Neoadjuvant treatment for borderline...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Neoadjuvant treatment for borderline...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Neoadjuvant treatment for borderline...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Neoadjuvant treatment for borderline...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Neoadjuvant treatment for borderline...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Neoadjuvant treatment for borderline...